[
  {
    "ts": null,
    "headline": "Biogen Hits 52-Week High, Alzheimer's Drug Sales Jump",
    "summary": "Biogen Inc. (NASDAQ:BIIB) on Friday reported better-than-expected fourth-quarter earnings, with adjusted EPS of $1.99, beating the consensus of $1.59. The Alzheimer's drug maker reported revenues of $2.28 billion, beating the consensus of $2.20 billion, down 7% on a reported and constant currency basis. Drugs Performance Biogen on Friday said fiscal 2025 revenue from growth products increased 19% year-over-year and offset the year-over-year revenue decline from multiple sclerosis products, exclu",
    "url": "https://finnhub.io/api/news?id=a7eb5a3ccc36317d24d08fb6d62d9e7c5bdcf0629e13699c2ab9b9344c6d0819",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770589863,
      "headline": "Biogen Hits 52-Week High, Alzheimer's Drug Sales Jump",
      "id": 138397588,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen Inc. (NASDAQ:BIIB) on Friday reported better-than-expected fourth-quarter earnings, with adjusted EPS of $1.99, beating the consensus of $1.59. The Alzheimer's drug maker reported revenues of $2.28 billion, beating the consensus of $2.20 billion, down 7% on a reported and constant currency basis. Drugs Performance Biogen on Friday said fiscal 2025 revenue from growth products increased 19% year-over-year and offset the year-over-year revenue decline from multiple sclerosis products, exclu",
      "url": "https://finnhub.io/api/news?id=a7eb5a3ccc36317d24d08fb6d62d9e7c5bdcf0629e13699c2ab9b9344c6d0819"
    }
  }
]